TRXBTRex Bio, Inc.
Clinical-stage biopharma developing immunoregulatory medicines, including TNFR2 agonist TRB-061, to restore immune balance in autoimmune/inflammatory diseases.
Company description (source: StockAnalysis)
TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines. It develops medicines that helps restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. The company’s product pipeline focuses on augmenting tissue Tregs to address critical treatment gaps and offers TRB-061, a phase 1 trial TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balanc...
51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.
Talk to us